Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea. Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea. Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51–358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32–366 d), which was significantly earlier than the median of 184 days (IQR 68–356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75–213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death. Conclusions: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.
Abstract
Background/Aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea. Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea. Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51–358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32–366 d), which was significantly earlier than the median of 184 days (IQR 68–356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75–213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death. Conclusions: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.
참고문헌 (32)
- "Global tuberculosis report 2022" (2022)[URL]
- Lee H, "Characteristics and trends of tuberculosis deaths in the Republic of Korea, 2021", Public Health Weekly Report, 16, pp.563~577 (2023)
- Chung-Delgado K, "Mortality among MDR-TB cases : comparison with drug-susceptible tuberculosis and associated factors", PLoS One, 10, pp.e0119332~ (2015)
- Nicholson TJ, "A systematic review of risk factors for mortality among tuberculosis patients in South Africa", Syst Rev, 12, pp.23~ (2023)
- Sun Y, "Comparison of characteristics and mortality in multidrug resistant(MDR)and non-MDR tuberculosis patients in China", BMC Public Health, 15, pp.1027~ (2015)
- Alemu A, "Predictors of mortality in patients with drug-resistant tuberculosis : a systematic review and meta-analysis", PLoS One, 16, pp.e0253848~ (2021)
- Edessa D, "Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa : a meta-analysis of 43 cohort studies", PLoS One, 16, pp.e0261149~ (2021)
- Min J, "Clinical profiles of early and tuberculosis-related mortality in South Korea between 2015 and 2017 : a cross-sectional study", BMC Infect Dis, 19, pp.735~ (2019)
- Kwon YS, "Risk factors for death during pulmonary tuberculosis treatment in Korea : a multicenter retrospective cohort study", J Korean Med Sci, 29, pp.1226~1231 (2014)
- Lee J, "Comparison of early and late tuberculosis deaths in Korea", J Korean Med Sci, 32, pp.700~703 (2017)
- Chung S, "The relationship between socio-demographic factors and tuberculosis mortality in the Republic of Korea during 2008-2017", Front Public Health, 9, pp.691006~ (2021)
- Jeong D, "Cohort profile : Korean Tuberculosis and Post-Tuberculosis Cohort constructed by linking the Korean National Tuberculosis Surveillance System and National Health Information Database", J Prev Med Public Health, 55, pp.253~262 (2022)
- Choi H, "Nationwide treatment outcomes of patients with multidrug", rifampin-resistant tuberculosis in Korea, 2011-2017 : a retrospective cohort study(Korean TB-POST), 2023, pp.38, e33~
- Choi H, "Retreatment after loss to follow-up reduces mortality in patients with multidrug", rifampicin-resistant tuberculosis, 2023, pp.9, 00135-2023~
- "Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020" (2013)[URL]
- Hwang H, "Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid", Clin Infect Dis, 73, pp.1362~1369 (2021)
- Mok J, "9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis(MDR-END) : a multicentre, randomised, open-label phase 2", 3 non-inferiority trial in South Korea, 2022, pp.400, 1522~1530
- Nyang’wa BT, "A 24-week, all-oral regimen for rifampin-resistant tuberculosis", N Engl J Med, 387, pp.2331~2343 (2022)
- Waitt CJ, "A systematic review of risk factors for death in adults during and after tuberculosis treatment", Int J Tuberc Lung Dis, 15, pp.871~885 (2011)
- Hagiya H, "Trends in incidence and mortality of tuberculosis in Japan : a population-based study, 1997-2016", Epidemiol Infect, 147, pp.e38~ (2018)
- Pedrazzoli D, "Trends and risk factors for death and excess all-cause mortality among notified tuberculosis patients in the UK : an analysis of surveillance data", ERJ Open Res, 5, pp.00125-2019~ (2019)
- Negin J, "Tuberculosis among older adults--time to take notice", Int J Infect Dis, 32, pp.135~137 (2015)
- Byng-Maddick R, "Does tuberculosis threaten our ageing populations?", BMC Infect Dis, 16, pp.119~ (2016)
- Barrett J, "Why are people still dying from TB in low-burden countries?", Int J Tuberc Lung Dis, 26, pp.91~92 (2022)
- Min J, "Tuberculosis : Republic of Korea, 2021", Tuberc Respir Dis(Seoul), 86, pp.67~69 (2023)
- Teo AKJ, "Tuberculosis in older adults : case studies from four countries with rapidly ageing populations in the western pacific region", BMC Public Health, 23, pp.370~ (2023)
- Teo AKJ, "Tuberculosis in older adults : challenges and best practices in the Western Pacific Region", Lancet Reg Health West Pac, 36, pp.100770~ (2023)
- Duarte R, "Tuberculosis, social determinants and co-morbidities(including HIV)", Pulmonology, 24, pp.115~119 (2018)
- Samuels JP, "Comorbidities and treatment outcomes in multidrug resistant tuberculosis : a systematic review and meta-analysis", Sci Rep, 8, pp.4980~ (2018)
- Mutembo S, "Urban-rural disparities in treatment outcomes among recurrent TB cases in Southern Province, Zambia", BMC Infect Dis, 19, pp.1087~ (2019)
- Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis : an individual patient data meta-analysis", Lancet, 392, pp.821~834 (2018)
- Schnippel K, "Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis : a retrospective cohort study", Lancet Respir Med, 6, pp.699~706 (2018)